Histological classification of malignant renal tumours at a time of major diagnostic and therapeutic changes

2004 Tsui, 2000, Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria, J Urol, 163, 1090, 10.1016/S0022-5347(05)67699-9 Novara, 2007, Grading systems in renal cell carcinoma, J Urol, 177, 430, 10.1016/j.juro.2006.09.034 Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 Warren, 2005, The Bosniak classification of renal cystic masses, BJU Int, 95, 939, 10.1111/j.1464-410X.2005.05442.x Eble, 1998, Extensively cystic renal neoplasms: cystic nephroma, cystic partially differentiated nephroblastoma, multilocular cystic renal cell carcinoma, and cystic hamartoma of renal pelvis, Semin Diagn Pathol, 15, 2 Zhou, 2009, Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence, Am J Surg Pathol, 33, 72, 10.1097/PAS.0b013e3181852105 Nassir, 2002, Multilocular cystic renal cell carcinoma: a series of 12 cases and review of the literature, Urology, 60, 421, 10.1016/S0090-4295(02)01742-9 Tickoo, 2006, Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia, Am J Surg Pathol, 30, 141, 10.1097/01.pas.0000185382.80844.b1 Argani, 2005, Translocation carcinomas of the kidney, Clin Lab Med, 25, 363, 10.1016/j.cll.2005.01.008 Bruder, 2004, Morphologic and molecular characterization of renal cell carcinoma in children and young adults, Am J Surg Pathol, 28, 1117, 10.1097/01.pas.0000131558.32412.40 Camparo, 2008, Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature, Am J Surg Pathol, 32, 656, 10.1097/PAS.0b013e3181609914 Argani, 2001, Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents, Am J Pathol, 159, 179, 10.1016/S0002-9440(10)61684-7 Argani, 2002, PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t (X;1) (p11.2;q21), Am J Surg Pathol, 26, 1553, 10.1097/00000478-200212000-00003 Malouf, 2011, Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors, J Urol, 185, 24, 10.1016/j.juro.2010.08.092 Malouf, 2010, Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network, Ann Oncol, 4 Delahunt, 1997, Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors, Mod Pathol, 10, 537 Ferlicot, 2005, Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature, Virchows Arch, 447, 978, 10.1007/s00428-005-0036-x Weber, 2003, Mucinous spindle cell carcinoma of the kidney. A molecular analysis, Pathologe, 24, 453, 10.1007/s00292-003-0657-2 Srigley, 2009, Uncommon and recently described renal carcinomas, Mod Pathol, 22, S2, 10.1038/modpathol.2009.70 Crotty, 1995, Chromophobe cell renal carcinoma: clinicopathological features of 50 cases, J Urol, 154, 964, 10.1016/S0022-5347(01)66944-1 Amin, 1997, Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases, Am J Surg Pathol, 21, 1, 10.1097/00000478-199701000-00001 Tickoo, 1999, Renal oncocytosis: a morphologic study of fourteen cases, Am J Surg Pathol, 23, 1094, 10.1097/00000478-199909000-00013 Pavlovich, 2002, Renal tumors in the Birt-Hogg-Dube syndrome, Am J Surg Pathol, 26, 1542, 10.1097/00000478-200212000-00002 Srigley, 1998, Collecting duct carcinoma of kidney, Semin Diagn Pathol, 15, 54 Cheng, 2008, Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior, Mod Pathol, 21, 647, 10.1038/modpathol.2008.44 Dixon, 2011, Tuberous sclerosis complex renal disease, Nephron Exp Nephrol, 118, e15, 10.1159/000320891 Eble, 1997, Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component, Am J Surg Pathol, 21, 1123, 10.1097/00000478-199710000-00001 Pea, 1998, Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma, Am J Surg Pathol, 22, 180, 10.1097/00000478-199802000-00005 Brimo, 2010, Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy, Am J Surg Pathol, 34, 715, 10.1097/PAS.0b013e3181d90370 Banumathy, 2010, Signaling pathways in renal cell carcinoma, Cancer Biol Ther, 10, 658, 10.4161/cbt.10.7.13247 Clark, 2009, The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy, Kidney Int, 76, 939, 10.1038/ki.2009.296 Patard, 2007, Prognostic factors in kidney cancer, Prog Urol, 17, 139 Choueiri, 2008, von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma, J Urol, 180, 860, 10.1016/j.juro.2008.05.015 Giubellino, 2009, Targeting the Met signaling pathway in renal cancer, Expert Rev Anticancer Ther, 9, 785, 10.1586/era.09.43 Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nat Genet, 16, 68, 10.1038/ng0597-68 Tsuda, 2007, TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition, Cancer Res, 67, 919, 10.1158/0008-5472.CAN-06-2855 Peruzzi, 2006, The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells, Proc Natl Acad Sci U S A, 103, 14531, 10.1073/pnas.0606850103 Berthou, 2004, The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants, Oncogene, 23, 5387, 10.1038/sj.onc.1207691 Betsunoh, 2007, Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma, Cancer Sci, 98, 491, 10.1111/j.1349-7006.2007.00412.x Lu, 2011, Therapeutic targeting the loss of the birt-hogg-dube suppressor gene, Mol Cancer Ther, 10, 80, 10.1158/1535-7163.MCT-10-0628 Kenerson, 2007, Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms, Hum Pathol, 38, 1361, 10.1016/j.humpath.2007.01.028 Davies, 2011, Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial, Clin Cancer Res, 17, 4071, 10.1158/1078-0432.CCR-11-0445